Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

NCT05512364 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT05512364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 3
Overall status
Recruiting
Start date
December 15, 2023
Completion date
November 1, 2035
Enrollment
220 (estimated)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

er-positive breast cancer, her2-negative breast cancer, stage iib breast cancer, stage iii breast cancer